Adam Mazurek1, MD, PhD; Anna Borratynska2, MD, PhD; Krzysztof P. Malinowski3,4; Mateusz Brozda1, MSc; Urszula Gancarczyk1, MD; Natalia Dluzniewska1, MD; Lukasz Czyz1, MD; Martyna Duplicka1, MD; Ewa Sobieraj1, MD; Mariusz Trystula5, MD, PhD; Tomasz Drazkiewicz5, MD, PhD; Piotr Podolec1, MD, PhD; Piotr Musialek1, MD, DPhil
1. Jagiellonian University, Department of Cardiac & Vascular Diseases, John Paul II Hospital, Krakow, Poland; 2. Neurology Outpatient Department, John Paul II Hospital, Krakow, Poland; 3. KCRI Data Management Division, Krakow, Poland; 4. Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland; 5. Department of Vascular Surgery, John Paul II Hospital, Krakow, Poland
Large clinical series of carotid artery stenting (CAS) using conventional carotid stents have shown that 40-80% of adverse neurologic events within the first 30 days occur post-procedurally rather than intraprocedurally, and often several days after the procedure1. Indeed, first-generation carotid stent use is associated with post-procedural cerebral embolism2 that largely results from intraluminal plaque prolapse through the struts3, a phenomenon which is not eliminated by the classic closed-cell design4.
Sequential cerebral imaging with diffusion-weighted magnetic resonance (including routine imaging at baseline, 24-48 hours and 30 days5) demonstrated that the MicroNET-covered embolic prevention stent CGuard™ (InspireMD, Tel Aviv, ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Interventions for strokeCarotid stentingIschaemic stroke
Read next article
An obituary for Professor Tony Gershlick – 1951-2020